Identificador persistente para citar o vincular este elemento: http://hdl.handle.net/10553/112559
Título: Updated Analysis From KEYNOTE-189: Pembrolizumab or Placebo Plus Pemetrexed and Platinum for Previously Untreated Metastatic Nonsquamous Non-Small-Cell Lung Cancer
Autores/as: Gadgeel, S
Rodríguez Abreu, Delvys 
Speranza, G
Esteban, E
Felip, E
Domine, M
Hui, RN
Hochmair, MJ
Clingan, P
Powell, SF
Cheng, SYS
Bischoff, HG
Peled, N
Grossi, F
Jennens, RR
Reck, M
Garon, EB
Novello, S
Rubio-Viqueira, B
Boyer, M
Kurata, T
Gray, JE
Yang, J
Bas, T
Pietanza, MC
Garassino, MC
Clasificación UNESCO: 32 Ciencias médicas
320101 Oncología
Palabras clave: KEYNOTE-189
Pembrolizumab
Placebo
Pemetrexed
Non–small-cell lung cancer
Fecha de publicación: 2020
Publicación seriada: Journal of Clinical Oncology 
Resumen: PURPOSE In KEYNOTE-189, first-line pembrolizumab plus pemetrexed-platinum significantly improved overall survival (OS) and progression-free survival (PFS) compared with placebo plus pemetrexed-platinum in patients with metastatic nonsquamous non‒small-cell lung cancer (NSCLC), irrespective of tumor programmed death-ligand 1 (PD-L1) expression. We report an updated analysis from KEYNOTE-189 (ClinicalTrials.gov: NCT02578680). METHODS Patients were randomly assigned (2:1) to receive pemetrexed and platinum plus pembrolizumab (n = 410) or placebo (n = 206) every 3 weeks for 4 cycles, then pemetrexed maintenance plus pembrolizumab or placebo for up to a total of 35 cycles. Eligible patients with disease progression in the placebo-combination group could cross over to pembrolizumab monotherapy. Response was assessed per RECIST (version 1.1) by central review. No alpha was assigned to this updated analysis. RESULTS As of September 21, 2018 (median follow-up, 23.1 months), the updated median (95% CI) OS was 22.0 (19.5 to 25.2) months in the pembrolizumab-combination group versus 10.7 (8.7 to 13.6) months in the placebo-combination group (hazard ratio [HR], 0.56; 95% CI, 0.45 to 0.70]). Median (95% CI) PFS was 9.0 (8.1 to 9.9) months and 4.9 (4.7 to 5.5) months, respectively (HR, 0.48; 95% CI, 0.40 to 0.58). Median (95% CI) time from randomization to objective tumor progression on next-line treatment or death from any cause, whichever occurred first (progression-free-survival-2; PFS-2) was 17.0 (15.1 to 19.4) months and 9.0 (7.6 to 10.4) months, respectively (HR, 0.49; 95% CI, 0.40 to 0.59). OS and PFS benefits with pembrolizumab were observed regardless of PD-L1 expression or presence of liver/brain metastases. Incidence of grade 3-5 adverse events was similar in the pembrolizumab-combination (71.9%) and placebo-combination (66.8%) groups. CONCLUSION First-line pembrolizumab plus pemetrexed-platinum continued to demonstrate substantially improved OS and PFS in metastatic nonsquamous NSCLC, regardless of PD-L1 expression or liver/brain metastases, with manageable safety and tolerability.
URI: http://hdl.handle.net/10553/112559
ISSN: 0732-183X
DOI: 10.1200/JCO.19.03136
Fuente: Journal of Clinical Oncology [ISSN 0732-183X], v. 38(14), p. 1505-1517
Colección:Artículos
Adobe PDF (1,21 MB)
Vista completa

Google ScholarTM

Verifica

Altmetric


Comparte



Exporta metadatos



Los elementos en ULPGC accedaCRIS están protegidos por derechos de autor con todos los derechos reservados, a menos que se indique lo contrario.